Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:


IMMray™ is an antibody-based microarray technology that creates a snapshot of the immune system response from a single drop of blood.

Antibodies to relevant biomarkers are placed on a microarray and investigated using samples from diagnosed patients (retrospective studies). A series of advanced algorithms and bioinformatics are used to test which combination of biomarkers best identifies the disease. Thereafter, the IMMray™ platform software is trained to recognize the selected biomarker signature to a certain disease. In this way, we train the system until it is able to identify the patients with the best possible accuracy. Once training is complete, the biomarker signature is confirmed through prospective studies in our partner clinics and hospitals. We believe these unique “disease fingerprints” have the potential to provide a higher accurate diagnostic value than current practice, especially at early stages of disease.


Click on image below for larger size.


  1. Ingvarsson J et al.Proteomics 2008 8(11):2211-9.
  2. Wingren et al. Cancer Res. 2012 15;72(10):2481-90.
  3. Gerdtsson et al. Int Journal of Proteomics 2015;2015:587250.
  4. Gerdtsson et al. J Mol Oncol, 2016. 10, 1305-1316.
  5. Mellby et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. Journal of Clinical Oncology. 2018 Aug;36(28):2887-2894.